AI BriefingRoche Scales Up NVIDIA AI Factories Worldwide to Accelerate Drug Discovery and Manufacturing Innovation
Key point
Roche is expanding its AI infrastructure globally by deploying more than 3,500 NVIDIA Blackwell GPUs to boost drug discovery and manufacturing efficiency.
Details
Roche is deploying more than 3,500 NVIDIA Blackwell GPUs across its global operations to accelerate drug discovery, diagnostic solutions, and manufacturing innovation. This investment spans hybrid cloud and on-premises environments in the US and Europe, aiming to turn AI and accelerated computing into a core operational capability for the company.
In drug discovery, it supports Genentech's 'Lab-in-the-Loop' strategy. Using the NVIDIA BioNeMo platform and Blackwell GPUs, the company trains biological and molecular foundation models, iteratively connecting experiments and data to maximize research speed.
AI adoption is already delivering the following results:
- 25% faster design of degrader molecules for oncology
- Backup drug candidate development time cut from more than 2 years to 7 months
The company is also using NVIDIA Omniverse to build digital twins of manufacturing facilities. This enables it to simulate and optimize complex systems—such as the new GLP-1 manufacturing facility in North Carolina—before actual operation, improving manufacturing efficiency.
This summary was generated automatically by AI. Check the original for the author's claims and context. Copyright belongs to the original author.
Our guide explains how the AI works. Report summary errors, attribution issues, or removal requests via Contact.
Related
HP Opens Orders for AI Workstation 'ZGX Fury' with GB300 SuperchipStanford and NVIDIA Release 'Contrastive Language Model' CLM with 9x Faster Inference